Protagonist Therapeutics, Inc.
PTGX
$46.28
$0.481.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 184.40% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 184.40% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 184.40% | -- | -- | -- | -- |
| SG&A Expenses | 11.20% | 32.58% | 2.92% | 73.27% | 21.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.69% | 20.36% | 1.43% | 35.04% | 1.19% |
| Operating Income | 450.05% | -8.16% | 8.41% | 672.75% | 163.12% |
| Income Before Tax | 388.98% | 1.39% | 18.64% | 724.66% | 179.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 381.70% | 2.62% | 20.40% | 714.80% | 179.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 381.70% | 2.62% | 20.40% | 714.80% | 179.94% |
| EBIT | 450.05% | -8.16% | 8.41% | 672.75% | 163.12% |
| EBITDA | 444.70% | -8.25% | 8.46% | 677.38% | 164.25% |
| EPS Basic | 366.67% | 6.70% | 26.28% | 610.96% | 165.22% |
| Normalized Basic EPS | 373.77% | 5.52% | 24.66% | 619.10% | 165.21% |
| EPS Diluted | 351.31% | 6.90% | 26.47% | 586.57% | 163.10% |
| Normalized Diluted EPS | 354.97% | 5.52% | 24.66% | 596.74% | 163.74% |
| Average Basic Shares Outstanding | 3.21% | 4.37% | 7.98% | 20.33% | 22.58% |
| Average Diluted Shares Outstanding | 7.46% | 4.37% | 7.98% | 25.75% | 25.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |